RHYTHM PHARMACEUTICALS Business Summary

```json { "business_summary": "Rhythm Pharmaceuticals, Inc. (RYTM) is a commercial-stage biopharmaceutical company that generates revenue primarily through the global sale of IMCIVREE (setmelanotide), a first-in-class melanocortin-4 receptor (MC4R) agonist. The company’s business model is centered on the commercialization of precision medicines for rare genetic neuroendocrine diseases, specifically targeting hyperphagia and severe obesity. As of early 2026, the company reported preliminary 2025 net product revenues of approximately $194 million, representing a 50% year-over-year increase. Revenue is geographically segmented into the United States, which accounts for roughly 69% of total sales, and international markets, which contribute the remaining 31%. Rhythm maintains a dominant market position as a pioneer in the rare obesity space, holding a significant first-mover advantage over direct competitors such as Palatin Technologies, BioNTech, and Soleno Therapeutics. The company was founded by Bart Henderson and is currently led by Chairman, President, and CEO David Meeker, M.D., who previously served as the head of Sanofi Genzyme and CEO of KSQ Therapeutics. The executive leadership team includes Chief Financial Officer Hunter C. Smith, formerly of Celgene, Chief Technical Officer Joseph Shulman, and Chief Scientific Officer Alastair Garfield. This team brings deep pedigree in rare disease commercialization and global market access, exemplified by Executive Vice President Yann Mazabraud’s extensive background at Sanofi Genzyme. Rhythm is backed by a high-profile roster of institutional investors and board members, including Third Rock Ventures, Pfizer Venture Investments, RA Capital Management, Baker Bros. Advisors, and Perceptive Advisors, reflecting strong institutional confidence in its MC4R pathway pipeline." } ```